Background: There is growing evidence about the relationship between sleep quality (SQ) and disease activity in inflammatory bowel disease (IBD). This study aimed to identify the prevalence of sleep disturbance in IBD and its predictive factors and to assess its association with worse outcome. Methods: IBD patients were prospectively enrolled. Clinical activity, inflammatory activity (high C-reactive protein or fecal calprotectin), and SQ (assessed using the Pittsburgh Sleep Quality Index) were evaluated, and logistic regression was used to identify predictors of poor SQ at baseline. The development of disability or disease progression at 6 months (surgery, hospitalization, development of stenosis, penetrating or perianal disease, steroid dependency, or start/change immunosuppression) was compared between patients with and without poor SQ. Results: Two hundred and five patients were enrolled, with 44.9% (n = 92) reporting poor SQ. On multivariate analysis, current smoking (OR 2.80), extraintestinal manifestations (OR 2.68), clinical activity (OR 3.31), and inflammatory activity (OR 4.62) were predictive factors of poor SQ. Cox proportional hazards model showed that poor SQ was predictive of worse prognosis at 6 months (HR 2.470). Conclusion: There is a high prevalence of poor SQ in IBD patients, highlighting the importance of its inclusion in patient-reported outcomes. Sleep disturbance seems to have prognostic value in IBD.

1.
Abraham
C
,
Cho
JH
.
Inflammatory bowel disease
.
N Engl J Med
.
2009
;
361
(
21
):
2066
78
. .
2.
Ranjbaran
Z
,
Keefer
L
,
Stepanski
E
,
Farhadi
A
,
Keshavarzian
A
.
The relevance of sleep abnormalities to chronic inflammatory conditions
.
Inflamm Res
.
2007
;
56
:
51
7
.
3.
Kinnucan
JA
,
Rubin
DT
,
Ali
T
.
Sleep and inflammatory bowel disease: exploring the relationship between sleep disturbances and inflammation
.
Gastroenterol Hepatol
.
2013
;
9
(
11
):
718
27
.
4.
Preuss
F
,
Tang
Y
,
Laposky
AD
,
Arble
D
,
Keshavarzian
A
,
Turek
FW
.
Adverse effects of chronic circadian desynchronization in animals in a “challenging” environment
.
Am J Physiol Regul Integr Comp Physiol
.
2008
;
295
(
6
):
R2034
40
. .
5.
Amara
J
,
Saliba
Y
,
Hajal
J
,
Smayra
V
,
Bakhos
JJ
,
Sayegh
R
,
Circadian rhythm disruption aggravates DSS-induced colitis in mice with fecal calprotectin as a marker of colitis severity
.
Dig Dis Sci
.
2019
;
64
(
11
):
3122
33
. .
6.
Ali
T
,
Madhoun
MF
,
Orr
WC
,
Rubin
DT
.
Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients
.
Inflamm Bowel Dis
.
2013
;
19
(
11
):
2440
3
. .
7.
Wilson
RG
,
Stevens
BW
,
Guo
AY
,
Russell
CN
,
Thornton
A
,
Cohen
MA
,
High C-reactive protein is associated with poor sleep quality independent of nocturnal symptoms in patients with inflammatory bowel disease
.
Dig Dis Sci
.
2015
;
60
(
7
):
2136
43
. .
8.
Ranjbaran
Z
,
Keefer
L
,
Farhadi
A
,
Stepanski
E
,
Sedghi
S
,
Keshavarzian
A
.
Impact of sleep disturbances in inflammatory bowel disease
.
J Gastroenterol Hepatol
.
2007
;
22
(
11
):
1748
53
. .
9.
Lee
AJ
,
Kraemer
DF
,
Kanar
O
,
Berry
AC
,
Smotherman
C
,
Eid
E
.
Immunomodulator and biologic agent effects on sleep quality in patients with inflammatory bowel disease
.
Ochsner J
.
2018
;
18
(
1
):
76
80
.
10.
Michalopoulos
G
,
Vrakas
S
,
Makris
K
,
Tzathas
C
.
Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission
.
Ann Gastroenterol
.
2018 Mar–Apr
;
31
(
2
):
211
6
. .
11.
Sofia
MA
,
Lipowska
AM
,
Zmeter
N
,
Perez
E
,
Kavitt
R
,
Rubin
DT
.
Poor sleep quality in Crohn’s disease is associated with disease activity and risk for hospitalization or surgery [published online ahead of print, 2019 Dec 10]
.
Inflamm Bowel Dis
.
2020 Jul 17
;
26
(
8
):
1251
9
.
12.
Lonnfors
S
,
Vermeire
S
,
Greco
M
,
Hommes
D
,
Bell
C
,
Avedano
L
.
IBD and health-related quality of life: discovering the true impact
.
J Crohns Colitis
.
2014
;
8
:
1281
6
.
13.
Knowles
SR
,
Graff
LA
,
Wilding
H
,
Hewitt
C
,
Keefer
L
,
Mikocka-Walus
A
.
Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I
.
Inflamm Bowel Dis
.
2018
;
24
(
4
):
742
51
. .
14.
Peyrin-Biroulet
L
,
Sandborn
W
,
Sands
BE
,
Reinisch
W
,
Bemelman
W
,
Bryant
RV
,
Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target
.
Am J Gastroenterol
.
2015
;
110
(
9
):
1324
38
. .
15.
Bossuyt
P
,
Vermeire
S
.
Treat to target in inflammatory bowel disease
.
Curr Treat Options Gastroenterol
.
2016
;
14
(
1
):
61
72
. .
16.
Irvine
EJ
,
Feagan
B
,
Rochon
J
,
Archambault
A
,
Fedorak
RN
,
Groll
A
,
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group
.
Gastroenterology
.
1994
;
106
(
2
):
287
96
. .
17.
Del Rio João
KA
,
Becker
NB
,
de Neves Jesus
S
,
Isabel Santos Martins
R
.
Validation of the Portuguese version of the pittsburgh sleep quality index (PSQI-PT)
.
Psychiatry Res
.
2017
;
247
:
225
9
. .
18.
Ananthakrishnan
AN
,
Long
MD
,
Martin
CF
,
Sandler
RS
,
Kappelman
MD
.
Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis
.
Clin Gastroenterol Hepatol
.
2013
;
11
(
8
):
965
71
. .
19.
Marinelli
C
,
Savarino
EV
,
Marsilio
I
,
Lorenzon
G
,
Gavaruzzi
T
,
D’Incà
R
,
Sleep disturbance in Inflammatory Bowel disease: prevalence and risk factors: a cross-sectional study
.
Sci Rep
.
2020
;
10
(
1
):
507
. Published 2020 Jan 16. .
20.
Habibi
F
,
Mahdavi
SB
,
Khaniabadi
BM
,
Habibi
ME
,
Gharavinia
A
,
Baghaei
A
,
Sleep quality and associated factors in Iranian inflammatory bowel disease patients
.
J Res Med Sci
.
2019
;
24
:
59
. .
21.
Harbord
M
,
Annese
V
,
Vavricka
SR
,
Allez
M
,
Barreiro-de Acosta
M
,
Boberg
KM
,
The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease
.
J Crohns Colitis
.
March 2016
;
10
(
3
):
239
54
. .
22.
Marinelli
C
,
Savarino
E
,
Inferrera
M
,
Lorenzon
G
,
Rigo
A
,
Ghisa
M
,
Factors influencing disability and quality of life during treatment: a Cross-Sectional Study on IBD patients
.
Gastroenterol Res Pract
.
2019
;
2019
:
5354320
. Published 2019 Aug 21. .
23.
Gingold-Belfer
R
,
Peled
N
,
Levy
S
,
Katz
N
,
Niv
Y
,
Fass
R
,
Impaired sleep quality in Crohn’s disease depends on disease activity
.
Dig Dis Sci
.
2014
;
59
(
1
):
146
51
. .
24.
Sobolewska-Wlodarczyk
A
,
Wlodarczyk
M
,
Banasik
J
,
Gasiorowska
A
,
Wisniewska-Jarosinska
M
,
Fichna
J
.
Sleep disturbance and disease activity in adult patients with inflammatory bowel diseases
.
J Physiol Pharmacol
.
2018
;
69
(
3
). .
25.
Iskandar
HN
,
Linan
EE
,
Patel
A
,
Moore
R
,
Lasanajak
Y
,
Gyawali
CP
,
Self-reported sleep disturbance in Crohn’s disease is not confirmed by objective sleep measures
.
Sci Rep
.
2020
;
10
(
1
):
1980
. Published 2020 Feb 6. .
26.
Hao
G
,
Zhu
B
,
Li
Y
,
Wang
P
,
Li
L
,
Hou
L
.
Sleep quality and disease activity in patients with inflammatory bowel disease: a systematic review and meta-analysis
.
Sleep Med
.
2020 Sep 3
;
75
:
301
8
. Epub ahead of print. .
27.
Maaser
C
,
Sturm
A
,
Vavricka
SR
,
Kucharzik
T
,
Fiorino
G
,
Annese
V
,
ECCO-ESGAR Guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications
.
J Crohns Colitis
.
2019 Feb
;
13
(
2
):
144
64
.
28.
Reenaers
C
,
Bossuyt
P
,
Hindryckx
P
,
Vanpoucke
H
,
Cremer
A
,
Baert
F
.
Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice
.
United European Gastroenterol J
.
2018
;
6
(
8
):
1117
25
. .
29.
Stevens
BW
,
Borren
NZ
,
Velonias
G
,
Conway
G
,
Cleland
T
,
Andrews
E
,
Vedolizumab therapy is associated with an improvement in sleep quality and mood in inflammatory bowel diseases [published correction appears in Dig Dis Sci. 2017 Feb;62(2):552]
.
Dig Dis Sci
.
2017
;
62
(
1
):
197
206
.
30.
Szigethy
E
,
Hashash
J
,
Vachon
A
,
Mcauliff
K
,
Strassburger
M
,
Rode
N
,
P-034 brief behavioral intervention for sleep disturbance for adolescents and young adults with crohn’s disease: open trial study
.
Inflamm Bowel Dis
.
2016 Mar 1
;
22
(
Suppl 1
):
S20
.
31.
Thorkelson
G
,
Bielefeldt
K
,
Szigethy
E
.
Empirically supported use of psychiatric medications in adolescents and adults with IBD
.
Inflamm Bowel Dis
.
2016
;
22
(
6
):
1509
22
. .
32.
Qazi
T
,
Farraye
FA
.
Sleep and inflammatory bowel disease: an important bi-directional relationship
.
Inflamm Bowel Dis
.
2019
;
25
(
5
):
843
52
.
33.
Salwen-Deremer
JK
,
Siegel
CA
,
Smith
MT
.
Cognitive behavioral therapy for insomnia: a promising treatment for insomnia, pain, and depression in patients with IBD
.
Crohns Colitis 360
.
2020
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.